Assenagon Asset Management S.A. Purchases New Position in AC Immune $ACIU

Assenagon Asset Management S.A. purchased a new stake in AC Immune (NASDAQ:ACIU) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 189,892 shares of the company’s stock, valued at approximately $549,000. Assenagon Asset Management S.A. owned 0.19% of AC Immune at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sei Investments Co. bought a new stake in shares of AC Immune in the 2nd quarter worth about $51,000. Acadian Asset Management LLC boosted its position in AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares in the last quarter. Finally, BVF Inc. IL grew its stake in AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock worth $37,068,000 after buying an additional 300,000 shares during the last quarter. 51.36% of the stock is owned by institutional investors.

AC Immune Trading Down 1.4%

Shares of NASDAQ:ACIU opened at $3.11 on Friday. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.00. The stock has a market capitalization of $311.77 million, a P/E ratio of -3.70 and a beta of 1.60. The business has a 50-day moving average price of $3.10 and a two-hundred day moving average price of $2.61.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $0.81 million. AC Immune had a negative net margin of 1,642.89% and a negative return on equity of 84.32%. As a group, equities analysts predict that AC Immune will post -0.62 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of AC Immune from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, October 8th. Finally, BTIG Research restated a “buy” rating and set a $8.00 target price on shares of AC Immune in a report on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, AC Immune presently has a consensus rating of “Hold” and a consensus target price of $10.00.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.